The discovery of dabigatran etexilate for the treatment of venous thrombosis
Introduction: Venous thromboembolism (VTE) can be life-threatening and requires anticoagulant treatment; for many years, vitamin K antagonists, e.g. warfarin, were the only oral anticoagulants available for long-term treatment. Although highly effective, they have many limitations including a slow o...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
30 May 2016
|
| In: |
Expert opinion on drug discovery
Year: 2016, Jahrgang: 11, Heft: 7, Pages: 717-731 |
| ISSN: | 1746-045X |
| DOI: | 10.1080/17460441.2016.1188077 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1080/17460441.2016.1188077
|
| Verfasserangaben: | Martin Feuring, Joanne van Ryn |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1679074873 | ||
| 003 | DE-627 | ||
| 005 | 20230427135336.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191017s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17460441.2016.1188077 |2 doi | |
| 035 | |a (DE-627)1679074873 | ||
| 035 | |a (DE-599)KXP1679074873 | ||
| 035 | |a (OCoLC)1341248103 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Feuring, Martin |d 1963-2018 |e VerfasserIn |0 (DE-588)1075744083 |0 (DE-627)833665383 |0 (DE-576)176498125 |4 aut | |
| 245 | 1 | 4 | |a The discovery of dabigatran etexilate for the treatment of venous thrombosis |c Martin Feuring, Joanne van Ryn |
| 264 | 1 | |c 30 May 2016 | |
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 17.10.2019 | ||
| 520 | |a Introduction: Venous thromboembolism (VTE) can be life-threatening and requires anticoagulant treatment; for many years, vitamin K antagonists, e.g. warfarin, were the only oral anticoagulants available for long-term treatment. Although highly effective, they have many limitations including a slow onset, a multitude of drug-drug and drug-food interactions, and a narrow therapeutic range. These limitations spurred the search for non-vitamin K antagonist oral anticoagulants (NOACs), such as dabigatran etexilate.Areas covered: The authors illustrate the progression of preclinical and clinical studies leading to the development of dabigatran, the only approved NOAC to act by direct thrombin inhibition. They focus on molecule discovery, animal models of thrombosis, clinical trials and post-launch activities in VTE treatment.Expert opinion: Dabigatran demonstrated comparable efficacy to the highly effective warfarin, and a more favourable safety profile in trials of VTE treatment. A favourable anticoagulant safety profile in addition to efficacy is essential for VTE treatment. Availability of the dabigatran-specific reversal agent, idarucizumab, provides a means of rapidly reversing the anticoagulant effect if required. Future investigations into the optimal duration of VTE treatment and an evaluation of the impact of idarucizumab, in real-world studies, could provide valuable information to help optimise treatment for selected patients. | ||
| 650 | 4 | |a Dabigatran etexilate | |
| 650 | 4 | |a deep vein thrombosis | |
| 650 | 4 | |a direct thrombin inhibitors | |
| 650 | 4 | |a non-vitamin K antagonist oral anticoagulants | |
| 650 | 4 | |a pharmacology | |
| 650 | 4 | |a prevention | |
| 650 | 4 | |a pulmonary embolism | |
| 650 | 4 | |a treatment | |
| 650 | 4 | |a venous thromboembolism | |
| 700 | 1 | |a Ryn, Joanne van |e VerfasserIn |0 (DE-588)1197274243 |0 (DE-627)1679074857 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug discovery |d Abingdon : Taylor & Francis Group, 2006 |g 11(2016), 7, Seite 717-731 |h Online-Ressource |w (DE-627)525478329 |w (DE-600)2272966-5 |w (DE-576)302970312 |x 1746-045X |7 nnas |a The discovery of dabigatran etexilate for the treatment of venous thrombosis |
| 773 | 1 | 8 | |g volume:11 |g year:2016 |g number:7 |g pages:717-731 |g extent:15 |a The discovery of dabigatran etexilate for the treatment of venous thrombosis |
| 856 | 4 | 0 | |u https://doi.org/10.1080/17460441.2016.1188077 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20191017 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1075744083 |a Feuring, Martin |m 1075744083:Feuring, Martin |d 60000 |e 60000PF1075744083 |k 0/60000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1679074873 |e 3523523389 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"The discovery of dabigatran etexilate for the treatment of venous thrombosis","title_sort":"discovery of dabigatran etexilate for the treatment of venous thrombosis"}],"person":[{"given":"Martin","family":"Feuring","role":"aut","display":"Feuring, Martin","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Ryn, Joanne van","roleDisplay":"VerfasserIn","given":"Joanne van","family":"Ryn"}],"recId":"1679074873","language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 17.10.2019"],"id":{"doi":["10.1080/17460441.2016.1188077"],"eki":["1679074873"]},"origin":[{"dateIssuedDisp":"30 May 2016","dateIssuedKey":"2016"}],"name":{"displayForm":["Martin Feuring, Joanne van Ryn"]},"relHost":[{"title":[{"title":"Expert opinion on drug discovery","title_sort":"Expert opinion on drug discovery"}],"pubHistory":["1.2006 -"],"part":{"extent":"15","text":"11(2016), 7, Seite 717-731","volume":"11","issue":"7","pages":"717-731","year":"2016"},"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"The discovery of dabigatran etexilate for the treatment of venous thrombosisExpert opinion on drug discovery","note":["Gesehen am 11.04.16"],"language":["eng"],"recId":"525478329","origin":[{"dateIssuedKey":"2006","publisher":"Taylor & Francis Group ; Informa Healthcare","dateIssuedDisp":"2006-","publisherPlace":"Abingdon ; London"}],"id":{"zdb":["2272966-5"],"eki":["525478329"],"issn":["1746-045X"]},"physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"15 S."}]} | ||
| SRT | |a FEURINGMARDISCOVERYO3020 | ||